logo

AstraZeneca mulling a $10-billion bid for Medivation – report

pharmafile | July 12, 2016 | News story | Manufacturing and Production, Sales and Marketing |ย ย AstraZeneca, Celgene, Medivation, Pfizer, Xtandi, cancer drug, merger and acquisitionย 

Anglo Swedish drug firm AstraZeneca (LSE: AZN) is considering a $10-billion takeover bid for Medivation (Nasdaq: MDVN), according to reports.

The company is said to have revived its interest in the Maker of prostate cancer drug Xtandi (enzalutamide) and potentially looking to join the fray.

Medivation has a promising pipeline of cancer drugs making it an attractive target for big pharma firms looking to bolster their portfolio amidst shrinking profits.

Advertisement

Last week, Medivation rejected a raised takeover offer from Sanofi of $58 a share in cash. Medivation has also disclosed that it signed confidentiality agreements regarding a potential transaction with several companies, including the French drugmaker.

Reports have also indicated to US pharma giant Pfizerโ€™s (NYSE: PFE) interest in Medivation for a potential takeover. Pfizer, as well as biotech firm Celgene (Nasdaq: CELD), are rumoured to be among the companies to have signed confidentially agreements with Medivation.

Anjali Shukla

Related Content

Astra Zeneca Logo

NICE recommends Benralizumab for Rare Form of Vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZenecaโ€™s benralizumab (Fasenra) as …

NICE approves AstraZenecaโ€™s dual immunotherapy for advanced liver cancer

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …

Astra Zeneca Logo

Purpose and people: the enduring power of brand and the evolution of employer identity

Two decades ago, terms like purpose and people were rarely at the forefront of branding …

The Gateway to Local Adoption Series

Latest content